Athira Pharma, Inc. (NASDAQ:ATHA) Director Acquires $66,308.00 in Stock

Athira Pharma, Inc. (NASDAQ:ATHA) Director Kelly A. Romano acquired 27,400 shares of the firm’s stock in a transaction that occurred on Monday, June 24th. The stock was acquired at an average price of $2.42 per share, for a total transaction of $66,308.00. Following the completion of the acquisition, the director now directly owns 80,715 shares of the company’s stock, valued at approximately $195,330.30. The purchase was disclosed in a legal filing with the SEC, which is accessible through this link.

Athira Pharma Trading Down 7.6 %

Shares of NASDAQ:ATHA traded down $0.18 during trading on Tuesday, hitting $2.19. 153,865 shares of the stock were exchanged, compared to its average volume of 304,757. Athira Pharma, Inc. has a 12-month low of $1.33 and a 12-month high of $4.30. The company has a market cap of $83.94 million, a PE ratio of -0.72 and a beta of 2.91. The company has a fifty day moving average price of $2.34 and a two-hundred day moving average price of $2.71.

Athira Pharma (NASDAQ:ATHA) last announced its quarterly earnings data on Wednesday, May 15th. The company reported ($0.69) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.80) by $0.11. Equities research analysts anticipate that Athira Pharma, Inc. will post -2.79 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, JMP Securities restated a “market outperform” rating and issued a $19.00 price target on shares of Athira Pharma in a research note on Thursday, June 20th.

Institutional Trading of Athira Pharma

Several hedge funds have recently made changes to their positions in the stock. Perceptive Advisors LLC grew its position in Athira Pharma by 12.6% in the 4th quarter. Perceptive Advisors LLC now owns 5,402,964 shares of the company’s stock valued at $13,129,000 after buying an additional 605,686 shares in the last quarter. Private Advisor Group LLC bought a new position in shares of Athira Pharma during the 4th quarter valued at about $32,000. Clarius Group LLC raised its holdings in shares of Athira Pharma by 35.8% in the 4th quarter. Clarius Group LLC now owns 53,551 shares of the company’s stock worth $130,000 after purchasing an additional 14,124 shares in the last quarter. Laird Norton Trust Company LLC lifted its stake in Athira Pharma by 21.3% during the third quarter. Laird Norton Trust Company LLC now owns 178,709 shares of the company’s stock valued at $361,000 after purchasing an additional 31,400 shares during the last quarter. Finally, Forefront Analytics LLC boosted its holdings in Athira Pharma by 43.0% during the fourth quarter. Forefront Analytics LLC now owns 29,765 shares of the company’s stock worth $72,000 after buying an additional 8,955 shares in the last quarter. Institutional investors own 57.12% of the company’s stock.

Athira Pharma Company Profile

Athira Pharma, Inc, a late clinical-stage biopharmaceutical company, focuses on developing small molecules to restore neuronal health and slow neurodegradation. Its lead product candidate is Fosgonimeton (ATH-1017), a small molecule designed to modulate the neurotrophic hepatocyte growth factor (HGF) system and its receptor, MET, for a healthy nervous system that is in LIFT-AD Phase 2/3 and ACT-AD Phase 2 clinical trials for the treatment of Alzheimer's disease, as well as is in Phase 2 clinical trials to treat Parkinson's disease dementia and Dementia with Lewy bodies.